PYXS: רווח נקי למניה (EPS TTM) Pyxis

Pyxis Oncology, Inc. (PYXS) develops patent platforms for immunotherapy that ensure high margins. However, clinical trial costs are creating a liquidity deficit. The rolling annual earnings per share chart visualizes these financial processes, where the latest parameter is -1.30. A portfolio of several targeted developments effectively mitigates risks associated with the failure of any single drug.

This metric reflects operational efficiency by distributing total net income across all outstanding shares, neutralizing short-term market distortions. Within the biotechnology sector, where Pyxis Oncology, Inc. (PYXS) faces intensive capital expenditure for clinical trials, the rolling year earnings per share serves as an indicator of financial stability and the cash burn rate.